Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Audentes Therapeutics Inc (BOLD)

Audentes Therapeutics Inc (BOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,656,446
  • Shares Outstanding, K 44,290
  • Annual Sales, $ 0 K
  • Annual Income, $ -128,820 K
  • 60-Month Beta 1.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.09
  • Number of Estimates 7
  • High Estimate -0.99
  • Low Estimate -1.23
  • Prior Year -0.85
  • Growth Rate Est. (year over year) -28.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.00 +7.31%
on 06/03/19
41.25 -8.95%
on 06/20/19
-0.54 (-1.42%)
since 05/24/19
3-Month
35.00 +7.31%
on 06/03/19
41.65 -9.82%
on 04/10/19
+0.94 (+2.57%)
since 03/26/19
52-Week
17.95 +109.25%
on 12/26/18
42.69 -12.03%
on 07/20/18
-2.76 (-6.85%)
since 06/26/18

Most Recent Stories

More News
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced...

BOLD : 37.46 (+0.16%)
Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced...

BOLD : 37.46 (+0.16%)
Audentes Therapeutics: 1Q Earnings Snapshot

SAN FRANCISCO (AP) _ Audentes Therapeutics Inc. (BOLD) on Tuesday reported a loss of $49.4 million in its first quarter.

BOLD : 37.46 (+0.16%)
Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported...

BOLD : 37.46 (+0.16%)
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced...

BOLD : 37.46 (+0.16%)
Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host...

BOLD : 37.46 (+0.16%)
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases,...

BOLD : 37.46 (+0.16%)
Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced...

BOLD : 37.46 (+0.16%)
Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced...

BOLD : 37.46 (+0.16%)
4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

QURE : 73.33 (-2.23%)
SLDB : 4.64 (-4.13%)
ONCE : 101.75 (+0.95%)
SRPT : 128.30 (+3.33%)
OPHT : 1.39 (-0.71%)
NITE : 25.41 (-0.04%)
RGNX : 48.76 (-3.02%)
BOLD : 37.46 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade BOLD with:

Business Summary

Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for...

See More

Key Turning Points

2nd Resistance Point 39.96
1st Resistance Point 38.68
Last Price 37.46
1st Support Level 36.56
2nd Support Level 35.72

See More

52-Week High 42.69
Last Price 37.46
Fibonacci 61.8% 33.24
Fibonacci 50% 30.32
Fibonacci 38.2% 27.40
52-Week Low 17.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar